Somatic genome editing with the RCAS/TVA-CRISPR/Cas9 system for precision tumor modeling

Barbara Oldrini(Spanish National Cancer Research Centre), Massimo Squatrito(AstraZeneca (United Kingdom))
bioRxiv (Cold Spring Harbor Laboratory)
August 14, 2017
10.1101/162669
Cited by 6

Related Papers

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
|Nature Communications|2020|195
Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4
|Nature|2022|88
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
|Nature Communications|2018|73
NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1
|bioRxiv (Cold Spring Harbor Laboratory)|2019|9